Aspen Pharmacare Holdings Limited (JSE:APN)
South Africa · Delayed Price · Currency is ZAR · Price in ZAc | Market Cap | 69.58B +51.6% |
| Revenue (ttm) | 34.87B -19.6% |
| Net Income | 2.65B |
| EPS | 5.96 |
| Shares Out | 444.02M |
| PE Ratio | 26.29 |
| Forward PE | 13.03 |
| Dividend | 2.32 (1.48%) |
| Ex-Dividend Date | Oct 7, 2026 |
| Volume | 544,788 |
| Open | 15,685 |
| Previous Close | 15,657 |
| Day's Range | 15,573 - 15,789 |
| 52-Week Range | 9,070 - 16,621 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 17,266.67 (+10.19%) |
| Est. Earnings | Dec 2, 2026 |
About Aspen Pharmacare Holdings
Aspen Pharmacare Holdings Limited, together with its subsidiaries, operates as a specialty and branded pharmaceutical company in Africa, the Middle East, Europe, CIS, Australasia, Asia, and the Americas. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers sterile products in injectable form primarily administered in hospitals and prescribed and administered by physicians or in a retail pharmacy environment for therapeutic areas, such as anesthetics, anticoagulants, antithrombotic agents, analgesics, and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for APN stock is "Buy." The 12-month stock price target is ZAC 17,267, which is an increase of 10.19% from the latest price.
News
Aspen sees Mounjaro Africa sales above $124 million in 2027
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging deman...
Aspen Pharmacare Holdings Earnings Call Transcript: H2 2026
Delivered strong EBITDA and NHEPS growth despite flat revenue, driven by operational efficiencies, robust commercial pharma performance, and a successful APAC divestment. FY 2027 guidance targets over ZAR 9 billion EBITDA, 50%+ NHEPS growth, and stronger free cash flow.
Aspen Pharmacare Holdings Annual report: H2 2026
Aspen Pharmacare Holdings has published its H2 2026 annual report on September 3, 2026.
Aspen Pharmacare Holdings Slides: H2 2026
Aspen Pharmacare Holdings has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 3, 2026.
South African drugmaker Aspen's earnings rise 22%
South Africa's Aspen Pharmacare reported on Wednesday a 22% rise in normalised earnings, supported by strong momentum in its commercial pharmaceuticals unit, which was the main driver of growth...
Aspen Pharmacare wins Canada approval for generic Ozempic injection
South Africa's Aspen Pharmacare said on Monday that its Canadian subsidiary had received regulatory approval from Health Canada for Aspen-Semaglutide, a generic semaglutide injectable used to...
Aspen Pharmacare Holdings Transcript: Status update
Completion of the APAC divestment delivered ZAR 28 billion in proceeds, strengthening the balance sheet and enabling a near net cash position. Focus now shifts to organic growth, profitability restoration, and potential share buybacks, leveraging strong free cash flow and existing assets.
Aspen Pharmacare Holdings Press release: Status update
Aspen Pharmacare Holdings issued a press release on May 29, 2026, disclosing material business information to investors.
Aspen Pharmacare Holdings Earnings Call Transcript: H1 2026
Revenue declined 4% year-over-year to ZAR 21 billion, driven by manufacturing losses, while commercial pharma delivered double-digit EBITDA growth. APAC divestment will eliminate debt and support future share buybacks, with guidance for strong H2 and double-digit normalized HEPS growth.
Aspen Pharmacare Holdings Quarterly report: H1 2026
Aspen Pharmacare Holdings has published its H1 2026 quarterly earnings report on March 4, 2026.
Aspen Pharmacare Holdings Slides: H1 2026
Aspen Pharmacare Holdings has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 4, 2026.
Aspen Pharmacare aims for Canada entry with Ozempic generic by third quarter
Aspen Pharmacare's unbranded version of Novo Nordisk's popular diabetes drug Ozempic could be registered in Canada in the second or third quarter of this year, the South African pharmacueticals g...
Aspen Pharmacare Holdings Quarterly report: Q2 2026
Aspen Pharmacare Holdings has published its Q2 2026 quarterly earnings report on February 11, 2026.
Aspen Pharmacare Holdings Transcript: Status update
Divestment of the APAC business for ZAR 26.5 billion will significantly reduce debt and enhance balance sheet flexibility, with proceeds used to drive organic growth in pharma and manufacturing. GLP-1s and contract manufacturing are key future growth drivers.
Aspen Pharmacare Holdings Press release: Status update
Aspen Pharmacare Holdings issued a press release on January 15, 2026, disclosing material business information to investors.
Aspen Pharmacare Holdings Slides: Status update
Aspen Pharmacare Holdings has posted slides in relation to its latest quarterly earnings report, which was published on January 15, 2026.
Aspen Pharmacare Holdings Earnings Call Transcript: H2 2025
Despite macroeconomic turbulence and a major contract loss, commercial pharma delivered strong growth, especially in Africa and Latin America. EBITDA and earnings were impacted by FX and tax changes, but cash conversion was robust. Outlook is positive, with focus on cost control, manufacturing turnaround, and GLP-1 opportunities.
Aspen Pharmacare Holdings Annual report: H2 2025
Aspen Pharmacare Holdings has published its H2 2025 annual report on September 4, 2025.
Aspen Pharmacare Holdings Annual report: H2 2025
Aspen Pharmacare Holdings has published its H2 2025 annual report on September 4, 2025.
Aspen Pharmacare Holdings Slides: H2 2025
Aspen Pharmacare Holdings has posted slides in relation to its H2 2025 quarterly earnings report, which was published on September 4, 2025.
Aspen Pharmacare Holdings Earnings Call Transcript: H1 2025
Strong H1 2025 results with double-digit CER growth in revenue and EBITDA, driven by robust commercial pharma and manufacturing performance. Strategic progress in GLP-1, insulin, and vaccine manufacturing positions the business for sustained growth, despite currency and tax headwinds.
Aspen Pharmacare Holdings Quarterly report: H1 2025
Aspen Pharmacare Holdings has published its H1 2025 quarterly earnings report on March 4, 2025.
Aspen Pharmacare Holdings Slides: H1 2025
Aspen Pharmacare Holdings has posted slides in relation to its H1 2025 quarterly earnings report, which was published on March 4, 2025.
Aspen Pharmacare Holdings Earnings Call Transcript: H2 2024
Revenue grew 10% year-over-year, driven by manufacturing and commercial pharma, with EBITDA and HEPS up 17% in H2. Strategic focus on GLP-1s and sterile manufacturing positions for strong future growth, while risks from regulatory timelines and pricing remain.
Aspen Pharmacare Holdings Annual report: H2 2024
Aspen Pharmacare Holdings has published its H2 2024 annual report on September 4, 2024.